Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors

MYE Symphony is a multicenter, open-label, Phase 1 first-in-human study to assess the safety, tolerability, and define the RP2D of MT-302 in participants with advanced epithelial cancer.

Trial Details

NCT ID
NCT05969041
Phase
PHASE1
Sponsor
Myeloid Therapeutics
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • MT-302 (A)
Locations (sample)
  • Darlinghurst, New South Wales, Australia|-33.87939,151.21925
  • Randwick, New South Wales, Australia|-33.91439,151.24895
  • Westmead, New South Wales, Australia|-33.80383,150.98768
  • Bedford Park, South Australia, Australia|-35.02204,138.56815
  • Malvern, Victoria, Australia|-37.86259,145.02811

Key Eligibility Criteria

  • Adults age ≥ 18 inclusive at the time the Informed Consent Form (ICF) is signed.
  • Histologically proven, metastatic or advanced epithelial cancer including the following cancer types:
  • Urothelial
  • Ovarian epithelial

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →